Bio Pharma Dive

JUNE 8, 2022

The biotech claims study results could position its reformulated vaccine as a booster in the fall, though it’s unclear how well the shot can prevent sickness caused by omicron or newer strains of the variant.

Immune Response 277

Immune Response Vaccination Vaccine 277

Bio Pharma Dive

AUGUST 16, 2024

The vaccine didn’t spur a strong enough immune response against a particular flu strain in a Phase 3 trial, leading the companies to ponder adjustments.

Immune Response 300

Immune Response Development Vaccination Vaccine 300

Bio Pharma Dive

OCTOBER 13, 2021

Results suggested Pfizer's and Moderna's vaccines may serve as a more potent booster for those who initially received Johnson & Johnson's shot, although data are limited and preliminary.

Immune Response 300

Immune Response Vaccination Vaccine 300

Bio Pharma Dive

SEPTEMBER 20, 2021

The results position Pfizer and BioNTech to seek clearance in children as young as five years old. But the companies haven't yet shared data on a rare heart inflammation associated with their shot that's a concern for regulators.

Immune Response 304

Immune Response Regulation Vaccination Vaccine 304

Medical Xpress

DECEMBER 13, 2022

Within a study by investigators at Weill Cornell Medicine and NewYork-Presbyterian, the long-term immune response to SARS-CoV-2 mRNA vaccination was similar in pregnant individuals and non-pregnant individuals of reproductive age.

Immune Response 97

Immune Response Vaccination Vaccine Medicine 97

BioPharma Reporter

OCTOBER 1, 2024

A head-to-head study has revealed that CSL and Arcturus Therapeuticâs self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a much lower dose.

Vaccination 105

Vaccination Vaccine Immune Response Development 105

Pharmaceutical Technology

APRIL 15, 2024

Discover ImmunityBio Inc's groundbreaking patent for a cross-reactive SARS-CoV2 vaccine targeting multiple variants. Learn how this innovative method boosts immune response and memory cells for enhanced protection.

Immune Response 147

Immune Response Vaccination Vaccine 147

Pharmaceutical Technology

JUNE 7, 2024

Discover Curevac NV's groundbreaking patent for an mRNA-based RSV vaccine, targeting prophylaxis and treatment. Learn about the innovative pharmaceutical composition and method for stimulating a robust immune response against RSV.

Immune Response 130

Immune Response Vaccination Vaccine Protein 130

Medical Xpress

APRIL 20, 2023

A new HIV vaccine from Scripps Research has shown a significantly improved ability to neutralize the virus in preclinical tests, and it will soon be studied in healthy people who volunteer to participate in clinical trials.

Immune Response 111

Immune Response Vaccination Vaccine Clinical Trials 111

Medical Xpress

JANUARY 4, 2023

Myocarditis, a condition in which the heart muscle becomes inflamed, is a rare complication that can occur after mRNA COVID vaccination. It's estimated that roughly 18 cases occur in every 1 million vaccine doses administered, making it so rare that it is challenging to find cases to investigate.

Immune Response 91

Immune Response Protein Vaccination Vaccine 91

Bio Pharma Dive

DECEMBER 10, 2021

Data from a small Phase 1 trial showed the biotech's vaccine spurred immune responses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi.

Immune Response 269

Immune Response Vaccination Vaccine Trials 269

BioSpace

NOVEMBER 1, 2020

Newly announced results of a Phase I dose-escalation study show CureVac’s COVID-19 vaccine candidate, CVnCoV, generates noticeable immune responses in healthy volunteers.

Immune Response 85

Immune Response Vaccination Vaccine 85

Fierce Pharma

SEPTEMBER 18, 2024

This summer, GSK cut its yearly vaccine sales projection o | In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.

Sales 110

Sales Vaccination Vaccine Immune Response 110

BioSpace

DECEMBER 10, 2020

The COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline hit a snag that will delay the launch of a Phase III study due to an insufficient immune response in older trial patients.

Immune Response 96

Immune Response Vaccination Vaccine Trials 96

BioSpace

OCTOBER 26, 2020

FDA greenlit the restart of AstraZeneca’s Phase III COVID-19 vaccine trial, the company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus. Days after the U.S.

Immune Response 89

Immune Response Vaccination Vaccine Trials 89

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. for serogroup W to 20.5

Vaccination 195

Vaccination Vaccine Immune Response Bacteria 195

Bio Pharma Dive

NOVEMBER 14, 2022

New results show the two-pronged booster the FDA cleared in August sparks a stronger immune response against omicron and its subvariants than Moderna’s original shot.

Immune Response 305

Immune Response Vaccination Vaccine 305

Pharmaceutical Technology

SEPTEMBER 20, 2024

Data showed non-inferiority of immune response between adults and adolescents with Imvanex.

Immune Response 130

Immune Response Vaccination Vaccine 130

The Pharma Data

OCTOBER 26, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Source link.

Immune Response 52

Immune Response Vaccination Vaccine Research 52

Scienmag

JUNE 2, 2022

Fever, cough, sore throat – symptoms in the spotlight in the era of COVID-19 – are just some of the tell-tale signs of our body’s immune system kicking into action against an unwanted intruder. Whether triggered by an infection, an allergen, or a vaccine, immune responses are driven by a complex array of cellular processes […].

Immune Response 63

Immune Response Vaccination Vaccine 63

Bio Pharma Dive

JULY 27, 2023

The pharma said its latest shot, which covers 21 strains of bacteria, cleared two Phase 3 trials and in some cases spurred a stronger immune response than Pfizer’s Prevnar 20.

Immune Response 245

Immune Response Bacteria Vaccination Vaccine 245

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

Immune Response 107

Immune Response Vaccination Vaccine Trials 107

BioPharma Reporter

FEBRUARY 4, 2021

A single-dose intranasal influenza vaccine is safe and produces a durable immune response, according to a Phase 1 study published in the Journal of Clinical Investigation this week.

Immune Response 52

Immune Response Vaccination Vaccine Development 52

The Pharma Data

OCTOBER 22, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Source link.

Immune Response 52

Immune Response Vaccination Vaccine Trials 52

Bio Pharma Dive

MARCH 23, 2022

Study results showed two shots of Moderna's vaccine led to similar immune responses as has been observed in young adults, although protection versus omicron was modest.

Immune Response 169

Immune Response Vaccination Vaccine 169

Pharmaceutical Technology

JUNE 16, 2023

France-based biotech company Osivax has thrown its hat into the influenza ring by dosing the first subject with its vaccine candidate OVX836. The Phase IIa trial (NCT05734040) in Australia will see a potential 500 volunteers given OVX836 in combination with quadrivalent influenza vaccines (QIVs).

Vaccination 246

Vaccination Vaccine Trials Immune Response 246

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccination 289

Vaccination Vaccine Development Immune Response 289

Pharmaceutical Technology

NOVEMBER 25, 2022

XtalPi has entered a strategic partnership with CK Life Sciences for artificial intelligence (AI)-driven tumour vaccine research and development (R&D). Under the collaboration, the companies will utilise their capabilities to co-develop a new AI tumour vaccine R&D platform.

Life Science 246

Life Science Vaccination Vaccine Development 246

Medical Xpress

APRIL 12, 2023

Testing the efficacy of a vaccine candidate is typically a long process, with the immune response of an animal model taking around two months.

Vaccination 124

Vaccination Vaccine Immune Response Development 124

Medical Xpress

APRIL 5, 2023

Adjuvants—ingredients that help boost the immune response in vaccines—have been used in vaccines for decades. But inducing a stronger immune response can result in more unwanted side effects, like swelling at the injection site or fever and body aches.

Immune Response 98

Immune Response Vaccination Vaccine 98

Medical Xpress

MARCH 2, 2023

The overall responsiveness of patients with chronic liver disease (CLD) to COVID-19 vaccines has been shown to be decreased in patients with cirrhosis.

Immune Response 83

Immune Response Vaccination Vaccine 83

BioPharma Reporter

MAY 17, 2021

Sanofi and GSK announced today that their COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in a Phase 2 trial.

Immune Response 64

Immune Response Vaccination Vaccine Trials 64

World of DTC Marketing

DECEMBER 29, 2020

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

Immune Response 71

Immune Response Vaccine Vaccination Development 71

Bio Pharma Dive

JANUARY 25, 2021

and South Africa, although the latter appeared to result in a weaker immune response. Laboratory tests indicated the biotech's shot would still protect against virus variants detected in the U.K.

Immune Response 306

Immune Response Vaccination Vaccine 306

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccination 245

Vaccination Vaccine Development RNA 245

Bio Pharma Dive

DECEMBER 11, 2020

The experimental shot produced a weak immune response in adults over 49, leading the partner drugmakers to change plans and push back their development timelines.

Immune Response 300

Immune Response Vaccination Vaccine Development 300